Earnings call transcript: WELL Health Q2 2025 shows strong growth despite stock dip

WELL Health Technologies Corp. reported robust Q2 2025 results, with revenue climbing 57% year-over-year to $356.7 million and adjusted EBITDA surging 231% to $49.7 million, both surpassing analyst forecasts. Despite this strong financial performance, the stock experienced a 4.78% decline in pre-market trading, possibly reflecting profit-taking or concerns over its high valuation. The company reaffirmed its 2025 revenue guidance and raised its adjusted EBITDA outlook, emphasizing a strategic pivot towards expanding its Canadian market share, divesting its U.S. care delivery assets, and planning an IPO for its Wellstar SaaS platform by early 2026.

Analysis

WELL Health Technologies Corp. (TSE: WELL) reported a robust second quarter for 2025, with revenue growing 57% year-over-year to $356.7 million and adjusted EBITDA surging 231% to $49.7 million, narrowly beating analyst expectations. Despite these strong results, the stock declined 4.78% in pre-market trading, a reaction potentially attributable to its high EBITDA multiple of 34.56x, an RSI suggesting an overbought condition, or simple profit-taking. The core of the company's strategy involves a significant pivot: divesting its U.S. care delivery assets (including Circle Medical and CRH) to unlock capital, and aggressively redeploying it into the fragmented Canadian healthcare market where it holds a dominant but still small 1.6% market share. This focus is underscored by the strong performance of its Canadian operations, which saw 40% revenue growth and 76% adjusted EBITDA growth. Further value-unlocking catalysts are on the horizon, including a planned IPO for its high-growth SaaS subsidiary, Wellstar, as early as Q4 2025, and the strategic streamlining of its majority-owned Healwell AI unit. Management has demonstrated confidence by increasing its full-year 2025 adjusted EBITDA guidance to the upper half of its $190 million to $210 million range, indicating improving profitability independent of future acquisitions.

Key Decisions for Investors

• Investors should assess WELL Health based on the execution of its strategic pivot, specifically monitoring for the successful divestiture of U.S. assets and the effective redeployment of capital into its Canadian M&A pipeline.
• The planned IPO of the Wellstar SaaS platform and the streamlining of Healwell AI are significant potential catalysts; progress and valuation on these fronts should be watched closely as they could unlock substantial value.
• While top-line growth is impressive, the stock's high valuation and negative market reaction to strong earnings suggest investors should be cautious of potential volatility and weigh the growth story against profitability metrics and execution risk.
• Monitor the company's ability to maintain M&A discipline, particularly its stated goal of achieving a 20% internal rate of return, as it accelerates its acquisition of Canadian clinics to expand its 1.6% market share.